Home-based high-intensity aerobic training was associated with greater improvement in cerebellar ataxia symptoms, fitness, and fatigue compared with guidelines-recommended balance training in a ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new drug ...

Should We Screen for Malignancies in People With ataxia telangiectasia? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

A Prescription Drug User Fee Act target date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Optic atrophy is a condition in which the optic nerve begins to deteriorate. The optic nerve is the nerve at the back of your eye that connects your eye to your brain, allowing you to see. There are a ...

Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Bill Nye the Science Guy is temporarily rebranding. For now, he’s ...

Skyclarys was approved in 2023 as the first treatment for FA. Skyclarys contains the active ingredient omaveloxolone. Skyclarys does not cure FA but may help to reduce symptoms and delay the worsening ...